What is the current stock price of Pulse Biosciences, Inc.?

As of the latest update, Pulse Biosciences, Inc.'s stock is trading at $48.54 per share.

What's happening with Pulse Biosciences, Inc. stock today?

Today, Pulse Biosciences, Inc. stock is down by 7.45%, possibly due to recent market activity.

What is the market sentiment around Pulse Biosciences, Inc. stock?

Current sentiment around Pulse Biosciences, Inc. stock is neutral, based on recent news, trading volume, and analyst opinions.

Is Pulse Biosciences, Inc.'s stock price growing?

Over the past month, Pulse Biosciences, Inc.'s stock price has decreased by 10.46%.

How can I buy Pulse Biosciences, Inc. stock?

You can buy Pulse Biosciences, Inc. stock through any brokerage platform, such as Robinhood, Fidelity, or E*TRADE, by searching for the ticker symbol PLSE.

Who are the major shareholders of Pulse Biosciences, Inc. stock?

Major shareholders of Pulse Biosciences, Inc. include institutions such as , according to the latest filings.

PLSE

Pulse Biosciences, Inc.

$48.54

7.45%

Trade Ideas Performance

Latest Closed Trade Idea

$48.54

7.45%

We are loading your data. Please wait a moment.

Sentiment

News

Social

About

Events of Pulse Biosciences, Inc. (PLSE)

In the past six months, Pulse Biosciences' stock significantly increased by 291.9% from $13.73 on January 1, 2026, to $53.81 by October 10, 2026. On October 7, 2026, the company achieved its enrollment target three months early in the NANOPULSE-AF IDE Pivotal Clinical Study for its nPulse Cardiac Catheter System. Pulse Biosciences announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on October 9, September 4, and August 18, 2026. The company's nPulse Technology was featured at the 21st Annual International VT Symposium 2026 on October 8, 2026. Quarterly earnings reported on August 6, 2026, missed consensus estimates for earnings per share and revenue. On September 15, 2026, Pulse Biosciences completed enrollment in the PRECISE-BTN Clinical Study for its nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The company surpassed the enrollment midpoint in its NANOPULSE-AF IDE Pivotal Study on July 29, 2026. In its first quarter 2026 financial results and business updates on May 4, 2026, Pulse Biosciences highlighted an accelerated enrollment timeline for the Cardiac Catheter IDE.

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Get started for FREE

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community